Search Results
Aug 25, 2026, 21:24 ET Caliway's CBL-514 Combination Therapy Cleared by U.S. FDA for Phase 2 Trial; Pivotal Phase 3 Trial SUPREME-01 Initiates Enrollment
FDA IND Clearance for CBL-0201WR—Caliway has cleared its Investigational New Drug application for CBL-0201WR, a Phase 2 trial evaluating CBL-514 in combination with tirzepatide.U.S. IRB Approval for Pivotal Phase 3 Trial SUPREME-01 (CBL-0301)—The protocol amendment for the pivotal
More news about: Caliway Biopharmaceuticals
Jul 15, 2026, 11:12 ET Voluntary Carbon Market to Reach USD 7.06 Bn by 2031; Spot Transactions Accounted for 53.61% of the Market in 2026, Says Mordor Intelligence
6.4.5 Climate Impact Partners 6.4.6 American Carbon Registry 6.4.7 3Degrees 6.4.8 CBL Xpansiv 6.4.9 Climate Impact X 6.4.10 CEEZER 6.4.11 Carbonfuture 6.4.12
More news about: Mordor Intelligence Private Limited
Jun 30, 2026, 09:00 ET Couchbase Launches the AI Data Plane, the Operational Data Foundation for the Agentic Enterprise
data and perform local vector search, even with intermittent or no connectivity.New innovations include:Couchbase Lite (CBL) 4.1: Native, out-of-the-box peer-to-peer sync over Bluetooth with automatic switching to Wi-Fi for more reliable collaboration in disconnected edge
More news about: Couchbase, Inc.
Jun 11, 2026, 00:54 ET Caliway Unveils Latest OI25 Animal Study Data for CBL-514 in Combination with GLP-1R-Based Weight-Loss Therapies at ADA 2026, Demonstrating Dual Potential to Attenuate Post-Discontinuation Weight Regain and Improve Metabolic Health
research on CBL–514 in combination with GLP–1R–based therapies and plans to advance to human clinical trials in the second half of 2026, while simultaneously strengthening the global clinical development and international licensing strategies for CBL–514.About CBL-514CBL-514 is a patented,
More news about: Caliway Biopharmaceuticals
Jun 10, 2026, 01:08 ET 康霈於美國糖尿病協會 ADA 2026 首度公開 CBL-514 併用「瘦瘦針」最新動物數據OI25, 展現「減緩復胖、改善代謝」雙重潛力
數據，則讓這項領先趨勢得到了更強而有力的科學驗證。展望未來，康霈將持續深化 CBL-514 與 GLP-1R 類藥物併用之研究，並規劃於今年下半年正式推進人體臨床試驗，持續加速 CBL-514 在全球體重管理、代謝健康領域的臨床開發與戰略佈局。關於 CBL-514CBL-514 注射劑是康霈生技自行研發的 505(b)(1) 全新小分子新藥，為全球首創透過誘導脂肪細胞凋亡（Apoptosis）來精準減少注射部位脂肪的局部減脂藥物。臨床試驗結果顯示，其療效與抽脂手術相當且安全性極佳，不會對周邊組織與細胞造成壞死或損傷。CBL-514 擁有多項適應症，包括減少皮下脂肪（非手術局部減脂）、中/重度橘皮組織（Cellulite）等；同成份不同劑型之新藥
More news about: 康霈生技
May 22, 2026, 03:09 ET Caliway Announces U.S. FDA IND Clearance for CBL-0302, Its Second Global Pivotal Phase 3 Study of CBL-514
Phase 3 clinical study application for CBL-0304 in China during the second half of 2026. Through this dual-track strategy, Caliway aims to deepen CBL-514's global regulatory footprint and commercialization readiness.About CBL-514CBL-514, developed by Caliway, is a first-in-class
More news about: Caliway Biopharmaceuticals
May 19, 2026, 06:08 ET 康霈 CBL-514 第二項全球樞紐三期試驗 CBL-0302 通過美國 FDA IND 30天審查期 二項樞紐三期臨床將同步推進
康霈局部減脂新藥 CBL-514 用於減少腹部皮下脂肪之第二項多國多中心樞紐三期臨床試驗 CBL-0302（SUPREME-02），已通過美國 FDA IND 30 天審查期，無回覆意見，將啟動 CBL-0302 臨床試驗。CBL-0302 預計於美國、加拿大與澳洲納入約 320 位受試者，並以 MRI 量測腹部皮下脂肪體積變化，以及以 PR-AFRS 評估腹部脂肪等級改善，作為主要療效指標。CBL-514 二項全球樞紐三期臨床試驗 CBL-0301 與 CBL-0302 皆預計於今年開始收案，並預計於 2027 年取得臨床試驗統計結果，共同作為未來新藥查驗登記（NDA）申請之關鍵三期臨床數據基礎。
More news about: 康霈生技
May 19, 2026, 01:19 ET Caliway Makes First ECO 2026 Oral Presentation on Preclinical Data of CBL-514 in Combination with GLP-1R-Based Weight-Loss Therapies, Attracting Strong Interest from International Experts and Global Pharmaceutical Companies for Its Systemic Metabolic Effects
enhancing the visibility of CBL-514 in the international obesity and metabolic medicine fields.The presentation covered animal study results of CBL-514 in combination with two leading GLP-1R-based weight-loss therapies, semaglutide and tirzepatide. The results showed that CBL-514, when combined with GLP-1R-based
More news about: Caliway Biopharmaceuticals
May 18, 2026, 04:31 ET 康霈首登 ECO 2026 口頭發表 CBL-514 併用 GLP-1R 類減重藥物動物數據 全身性代謝效果吸引國際專家及大藥廠高度興趣
反應的熱烈，以及會後與多家國際肥胖領域產業代表進一步交流可見，業界除了期待 CBL-514 局部減脂在醫美市場的臨床發展，對其未來於肥胖與代謝健康領域的潛在應用，也呈現越來越熱烈的關注。」除本次 ECO 2026 口頭發表外，CBL-514 與 GLP-1R 類藥物併用之動物實驗數據亦已獲選於6月的美國糖尿病協會年會（ADA 2026 Scientific Sessions）發表，將持續擴大 CBL-514 於全球糖尿病、肥胖與代謝醫學領域之國際代表性。康霈將持續深化 CBL-514 與 GLP-1R 類藥物併用之研究，並於今年推進人體臨床試驗，同時持續深化 CBL-514 全球臨床開發策略與國際授權布局。*關於CBL-514
More news about: 康霈生技
May 11, 2026, 10:50 ET The Cotocon Group Is Helping NYC Building Owners Navigate What Comes After Local Law 97 Filing Season
factors, wrong benchmarking data and improper ownership that doesn't match DOB records. Compliance pathways that are not up to date with the latest CBL."—
More news about: The Cotocon Group
May 05, 2026, 10:35 ET Enverus and Xpansiv broaden partnership to deliver a unified price discovery platform across energy and environmental markets through MarketView®
addition of CBL and Evolution Markets data extends that trusted foundation into environmental commodity markets.With the addition of CBL and Evolution Markets data from Xpansiv, market participants can now access:Verified exchange transactions and firm orders from CBL, the world's
More news about: Enverus
Apr 13, 2026, 04:34 ET Caliway's Fat Reduction Drug CBL-514 Phase 2 Clinical Results Accepted by ASJ. CBL-0204's Demonstrated Efficacy and Safety Gain Further Academic Recognition
highly meaningful to Caliway. This not only marks the third time that CBL-514 has received recognition from the internationally renowned ASJ, following CBL-16001 Phase 2a and CBL-0202 Phase 2 clinical results, but more importantly, CBL-0204's study design and efficacy endpoints are even highly aligned with
More news about: Caliway Biopharmaceuticals
Apr 02, 2026, 00:04 ET Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at the American Diabetes Association's 2026 Scientific Sessions
multinational pharmaceutical companies, to further expand and deepen the global development strategy and collaboration opportunities for CBL-514.About CBL-514CBL-514, a 505(b)(1) and first-in-class small-molecule drug developed by Caliway, is the world's first injectable lipolysis drug that
More news about: Caliway Biopharmaceuticals
Apr 01, 2026, 12:57 ET The Cotocon Group Warns NYC Building Owners: Local Law 97 "Grace Period" Is Creating a False Sense of Security
pathwaysFailure-to-file penalties due to unresolved discrepanciesRecent updates from NYC Buildings, including the consolidated Covered Buildings List (CBL) and stricter owner verification requirements, further reinforce the need for early and accurate action.May 1 Remains the Last Strategic AdvantageThe
More news about: The Cotocon Group
Mar 31, 2026, 20:49 ET 康霈獲選於美國糖尿病協會 ADA 2026 年會發表 CBL-514 與 GLP-1R 併用動物實驗數據
擔任發表講者，亦進一步提升康霈從局部減脂擴張至國際肥胖與代謝醫學領域的能見度與代表性。本次獲選發表之摘要標題為："Combination of Tirzepatide with CBL-514 an Adipocyte-Apoptosis Agent Improves Weight Loss Durability and Adipose Tissue Remodeling in Diet-Induced Obese Rats"（脂肪細胞凋亡誘導劑 CBL-514 聯合 Tirzepatide 可提升飲食誘導肥胖大鼠之減重持久性，並改善脂肪組織重塑）美國糖尿病協會（ADA）是國際深具權威的非營利醫學組織，每年所發布的《糖尿病照護標準》（Standards
More news about: 康霈生技
Mar 19, 2026, 20:50 ET Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at ECO 2026
obesity and metabolic disease fields during ECO 2026, with the goal of further advancing CBL-514's global development strategy and international collaboration efforts.About CBL-514CBL-514, a 505(b)(1) and first-in-class small-molecule drug developed by Caliway, is the world's first
More news about: Caliway Biopharmaceuticals
Mar 04, 2026, 09:00 ET World Youth Forum Concludes Inaugural Mainland China Summit, Hosting Record-Breaking National Finals for NEC and BPA
the academic rigor of the U.S.-based NEC and BPA with local industrial challenges, the event establishes a new benchmark for Challenge-Based Learning (CBL) in the region."WYF serves as a vital bridge, connecting Chinese youth to the global stage and amplifying their voice in international dialogue,"
More news about: World Youth Forum (WYF)
Mar 03, 2026, 09:46 ET The Cotocon Group: NYC Issues Borough-Specific Covered Buildings Lists for 2026, Signaling Structural Shift in Local Law 97 Compliance Administration
ProfessionalsEvery LL97-covered building should verify:That it appears correctly on the updated borough-specific CBLThat its assigned compliance pathway remains accurateThat its 2026 reporting and emissions strategy align with the updated classificationRegulatory
More news about: The Cotocon Group
Jan 26, 2026, 03:03 ET 康霈 CBL-514 竇根氏症二期成果獲登國際權威期刊《JAAD International》
康霈旗下全球首創之大範圍局部減脂新藥 CBL-514，用於治療罕病適應症—竇根氏症（Dercum's Disease）之二期臨床研究成果，已正式獲國際權威期刊《美國皮膚科醫學會雜誌JAAD International》刊登《JAAD International》為全球皮膚學領域具重要影響力的期刊之一，收錄標準嚴謹，影響因子5.2（Impact Factor 5.2），研究成果獲刊，代表其臨床價值與研究品質獲國際產學界的高度肯定。CBL-514 可顯著縮小痛性脂肪瘤超過 50% 甚至完全清除，並同步大幅降低疼痛分數，展現兼具「縮小脂肪瘤」與「改善疼痛」之雙重臨床價值此外，竇根氏症Phase
More news about: 康霈生技
Dec 24, 2025, 23:05 ET 康霈減脂新藥CBL-514完成美國FDA體重管理適應症二期臨床IND申請 擴展與GLP-1類減重藥聯用之研發布局
25%。顯示具差異化創新機轉及長期體重管理潜力之療法，仍有相當可觀的市場發展空間。*關於CBL-514 CBL-514注射劑是康霈生技自行研發的505(b)(1)全新小分子新藥，是全球首創透過誘導脂肪細胞凋亡來精準減少注射部位脂肪，根據其已完成的臨床試驗結果，療效優異與手術相當且安全性良好，不會造成其他細胞與組織壞死或明顯傷害。 CBL-514具有多項適應症，目前適應症包含減少皮下脂肪（非手術局部減脂）、中/重度橘皮組織（cellulite）及體重管理（Weight Management）等，同成份不同劑型之新藥CBL-514D適應症包含罕見疾病-竇根氏症（Dercum's
More news about: 康霈生技
Dec 24, 2025, 21:05 ET Caliway's Fat Reduction Drug Candidate CBL-514 Completes U.S. FDA IND Submission for Phase 2 Clinical Study in Weight Management, Expanding Development Combined with GLP-1RA-Based Weight-Loss Therapies
New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical study of CBL-514 for weight management (CBL-0201WR Phase 2).The study will evaluate CBL-514 in combination with Zepbound® (Eli Lilly) in subjects with obesity or overweight.Efficacy
More news about: Caliway Biopharmaceuticals
Dec 16, 2025, 00:35 ET Caliway Biopharmaceuticals Presents Preclinical Research Supporting a Multi-Mechanism Approach to Weight Management at TMASO 2025
TherapyDuring the presentation, Dr. Chou described CBL-514 as offering a mechanistically distinct approach compared with incretin-based therapies. While incretins primarily modulate appetite and energy intake, CBL-514 selectively induces apoptosis of adipocytes, thereby reducing
More news about: Caliway
Dec 05, 2025, 01:25 ET 康霈出席第四季法人論壇：揭示CBL-514聯用瘦瘦針最新動物數據 展現四大關鍵優勢、竇根氏症二期成果將獲登國際權威期刊JAAD
2.2 倍。CBL-514 透過「誘導脂肪細胞自然凋亡」的創新機轉，能直接減少脂肪細胞「數量」，與GLP-1 類藥物僅能使脂肪細胞「縮小」不同，進而能從源頭改善復胖問題，使停藥後有更佳的體重維持效果。3. 更健康的體組成改善： CBL-514單用即具強效減脂能力，併用後更可額外減少更多皮下脂肪（-182.5%）與內臟脂肪（-367.4%）。內臟脂肪為影響心血管風險的重要因子。此結果顯示CBL-514在健康體重管理上具高度應用潛力。4. CBL-514單用即具明顯皮下、內臟脂肪改善
More news about: 康霈生技
Oct 27, 2025, 06:50 ET Voluntary Carbon Credit Market - 50% CAGR for 2025-2030 Driven by Expanding Corporate Net-Zero Commitments, Reports Mordor Intelligence
American Carbon Registry (Winrock) Climate Action Reserve South Pole CBL (Xpansiv) Climate Impact X Patch Carbonplace
More news about: Mordor Intelligence Private Limited
Oct 13, 2025, 05:37 ET 康霈宣布實施庫藏股 展現維護公司長期價值信心；CBL-514全球授權談判加速擴大進行 歐洲糖尿病EASD會後新增數家國際藥廠
關於 CBL-514 CBL-514注射劑是康霈生技自行研發的505(b)(1)全新小分子新藥，是全球首創透過誘導脂肪細胞凋亡來精準減少注射部位脂肪，根據其已完成的臨床試驗結果，療效優異與手術相當且安全性良好，不會造成其他細胞與組織壞死或明顯傷害。 CBL-514具有多項適應症，目前適應症包含非手術局部減脂（減少皮下脂肪）、中/重度橘皮組織（cellulite）及改善復胖 — 體重管理（Weight Management）等，同成份不同劑型之新藥CBL-514D適應症包含罕見疾病-竇根氏症（Dercum's
More news about: Caliway